Ubs Group Ag Kazia Therapeutics LTD Put Options Transaction History
Ubs Group Ag
- $400 Billion
- Q2 2024
Put Options
0 transactions
| Quarter | Operation | Price Per put | puts change | puts Held | SEC Form |
|---|
Others Institutions Holding KZIA
# of Institutions
13Shares Held
328KCall Options Held
24KPut Options Held
0-
Morgan Stanley New York, NY201KShares$68,3670.0% of portfolio
-
Susquehanna International Group, LLP Bala Cynwyd, PA41.5KShares$14,1020.0% of portfolio
-
Virtu Financial LLC New York, NY39.3KShares$13,3540.0% of portfolio
-
Rhumbline Advisers Boston, MA17.6KShares$5,9890.0% of portfolio
-
Ken Griffin Citadel Advisors LLC | Chicago, Il4.57KShares$1,5520.0% of portfolio
About KAZIA THERAPEUTICS LTD
- Ticker KZIA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 15,111,300
- Market Cap $5.14M
- Description
- Kazia Therapeutics Limited, an oncology-focused biotechnology company, develops anti-cancer drugs. Its lead development candidate is Paxalisib, a small molecule, brain-penetrant inhibitor of the PI3K/Akt/mTor pathway, which is developed as a potential therapy for glioblastoma. It is also developing EVT801, an investigational new drug for various...